新橙皮苷作用機制 - Medchemexpress - MCE中國

1、Product Data SheetNeohesperidinCat. No.: HY-N0101CAS No.: 13241-33-3分式: CHO分量: 610.56作靶點: Others作通路: Others儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 DMSO : 100 mg/mL (163.78 mM; Need ultrasonic)SolventMass1 mg 5 mg 10 mgConcentration制備儲備液1 mM 1.6378 mL 8.1892 mL

2、 16.3784 mL5 mM 0.3276 mL 1.6378 mL 3.2757 mL10 mM 0.1638 mL 0.8189 mL 1.6378 mL請根據(jù)產品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；旦配成溶液，請分裝保存，避免反復凍融造成的產品失效。儲備液的保存式和期限：-80C, 6 months; -20C, 1 month。-80C 儲存時，請在 6 個內使，-20C 儲存時，請在 1 個內使。體內實驗請根據(jù)您的實驗動物和給藥式選擇適當?shù)娜芙獍?。以下溶解案都請先按?In Vitro 式配制澄清的儲備液，再依次添加助溶劑：為保證實驗結果的可靠性，澄 的儲備液可以根據(jù)儲存

3、條件，適當保存；體內實驗的作液，建議您現(xiàn)現(xiàn)配，當天使； 以下溶劑前顯的百分 指該溶劑在您配制終溶液中的體積占；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的式助溶1. 請依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (4.09 mM); Clear solution此案可獲得 2.5 mg/mL (4.09 mM，飽和度未知) 的澄清溶液。以 1 mL 作液為例，取 100 L 25.0 mg/mL 的澄 DMSO 儲備液加到 400 L PEG300 中，混合均勻；向上述體系中加

4、50 L Tween-80，混合均勻；然后繼續(xù)加 450 L 理鹽定容 1 mL。2. 請依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (4.09 mM); Clear solution此案可獲得 2.5 mg/mL (4.09 mM，飽和度未知) 的澄清溶液。Page 1 of 2 www.MedChemE以 1 mL 作液為例，取 100 L 25.0 mg/mL 的澄均勻。DMSO 儲備液加到 900 L 20% 的 SBE-CD 理鹽溶液中，混合3. 請依序添加每種溶劑： 10% DMSO 90%

5、corn oilSolubility: 2.5 mg/mL (4.09 mM); Clear solution此案可獲得 2.5 mg/mL (4.09 mM，飽和度未知) 的澄 溶液，此案不適于實驗周 期在半個以上的實驗。以 1 mL 作液為例，取 100 L 25.0 mg/mL 的澄 DMSO 儲備液加到 900 L 油中，混合均勻。BIOLOGICAL ACTIVITY物活性 Neohesperidin種量存在于葫蘆科植物中的類 酮化合物，具有抗氧化和抗炎作的。體外研究 Neohesperidin induces cell apoptosis in human breast adeno

6、carcinoma MDA-MB-231 cells. The IC50 values ofneohesperidin at 24 and 48 h are 47.42.6 M and 32.51.8 M, respectively. The expressions of P53 and Bax in theneohesperidin-treated cells are significantly up-regulated, while that of Bcl-2 is down-regulated1. Neohesperidinexhibits antioxidant activity (I

7、C50=22.31 g/mL) in the DPPH radical-scavenging assay2.體內研究 Neohesperidin (50 mg/kg) significantly inhibits 55.0% of HCl/ethanol-induced gastric lesions. In pylorus ligated rats,neohesperidin (50 mg/kg) significantly decreases the volume of gastric secretion and gastric acid output, andincreases the

8、pH1. Treatment of neohesperidin significantly decreases fasting glucose, serum glucose, andglycosylated serum protein (GSP) in mice. It significantly elevates oral glucose tolerance and insulin sensitivity anddecreases insulin resistance in the diabetic mice. Neohesperidin significantly decreases se

9、rum triglycerides, totalcholesterol, leptin level, and liver index in the mice3.PROTOCOLAnimal Mice: All the mice are fasted 6 h before the test and then fed with water or neohesperidin by gavage. The mice areAdministration 3 intraperitoneally injected with either 2 g/kg BW glucose or 1 IU/kg BW ins

10、ulin for OGTT and ITT, respectively. Bloodsamples are collected from the tail vein for the measurement of basal blood glucose levels (0 min) before theinjection of glucose or insulin. Additional blood glucose levels are measured at 30, 60, 90 and 120 min3.MCE has not independently confirmed the accu

11、racy of these methods. They are for reference only.REFERENCES1. Lee JH, et al. Protective effects of neohesperidin and poncirin isolated from the fruits of Poncirus trifoliata on potential gastric disease. Phytother Res.2009 Dec;23(12):1748-53.2. Xu F, et al. Neohesperidin induces cellular apoptosis

12、 in human breast adenocarcinoma MDA-MB-231 cells via activating the Bcl-2/Bax-mediatedsignaling pathway. Nat Prod Commun. 2012 Nov;7(11):1475-8.3. Jia S, et al. Hypoglycemic and hypolipidemic effects of neohesperidin derived from Citrus aurantium L. in diabetic KK-A(y) mice. Food Funct. 2015Mar;6(3):878-86.McePdfHeightPage 2 of 3 www.MedChemECaution: Product has not bee